Pharmaceutical companies will accelerate adoption of adaptive clinical trial designs, according to the Tufts Center for Drug Development, to reduce clinical development timelines and costs while ...

In the article that accompanies this editorial, Rahman et al 2 describe the results from the first three experimental arms of the INSIGhT trial which, to our knowledge, is the first adaptive platform ...

Response-adaptive designs allow the randomization probabilities to change during the course of a trial based on cumulated response data so that a greater proportion of patients can be allocated to the ...

A breast cancer screening study that pairs oncology therapies with biological markers (biomarkers) launched by a consortium of public health agencies, academics and companies is being heralded as a ...

The following represents disclosure information provided by the authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless ...